Keyword: Xellia Pharmaceuticals
After nearly five years Xellia Pharmaceuticals has started commercial production at former Boehringer Ingelheim sterile injectables plant.
Civica Rx, a hospital group committed to manufacturing its own drugs, has picked the first drugs it will make and the contractor to make them.
Japan’s Nichi-Iko Pharmaceutical and its U.S. operation Sagent Pharmaceuticals have bought a plant in North Carolina from Xellia.
Xellia Pharmaceuticals is hiring at the former Ben Venue Labs in Bedford, Ohio, as it prepares to begin drug manufacturing at the site next year.
Xellia Pharmaceuticals is investing $25 million to build additional sterile manufacturing capacity at its site in Copenhagen.
Xellia has completed a $13 million expansion at its facility in Hungary that will bolster the Danish API maker’s focus on anti-infective products.
The FDA will allow Xellia to begin packaging and labeling work at the former Boehringer Ingelheim plant that the Denmark company bought last year to expand its sterile manufacturing capacity. Xellia has added 90 employees and will add 80 more as it preps to start production at the facility in 2018.
Xellia Pharmaceuticals is expanding its manufacturing on a couple of fronts including work just started on a manufacturing facility in Hungary.
The notorious ex-Boehringer Ingelheim plant in Bedford, OH, is still governed by a court-ordered consent decree ordering improvements to be made before it is serviceable again. But Denmark’s Xellia, which bought the plant last year, says the FDA is cutting it some slack on the provisions so it can ready the facility for manufacturing next year.